Old API Wind-down Ltd - Ordinary Shares ARLZQ

Waikt .... What?

[WCoyote]

The list of BOD members to be voted for is:  Adrian Adams, Jason Aryeh, Neal Fowler, Rob Harris, Arthur Kirsch, Ken Lee, Seth Rudnick and Martin Thrasher.
 
What exactly is going on over there?  Apparently there is going to be no new blood over here.  Just the same old A$$holes that have overseen the demise of this company.
 
Well, I know how I’m going to vote – a resounding no to all of them.  I strongly suggest you all do the same.  Send a message!!!

[GoldenDilemma]

You are a small fish in the game. Retail don't make up this float. 

[WCoyote]

I know that, however it at the very least sends a message. BTW, the larger investors cannot be happy either.

[GoldenDilemma]

Any changes to management, count it as another kiss of death BTW...

[biggerr]

speaking of new blood, the launch of Zontivity this month could be a good stimulant for the SP, lots of folks have blood clots. I knew that the other drug would be a failure, you can't combine two existing drugs in one and hope it's a big deal

[kuatolives]

You also can't relaunch a product that already failed once and expect much success. Could be wrong, but, I doubt it.

[biggerr]

one big selling point for Zontivity is that it was invented by Merck which is a pharma giant

[biggerr]

Warfarin is a vitamin K antagonist but vitamin K is also needed to prevent osteoporosis and calcification while Zontivity has a different mechanism which is an advantage over warfarin. ARZ should use it as a major selling point

[CHECKMATE77]

You obviously did not major in pharmacology 

[biggerr]

what are you talking about, "vitamin K antagonist" means it shuts down the vitamin K so it can't coagulate blood but at the same time other functions of K are also impaired, you can't just shut off only one part of it, man

[CHECKMATE77]

It's not that part it's the other part of your statement its vit d that is for osteo not k as I said - you did not major in pharmacology